Print
|
Close
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Active:
Yes
Cancer Type:
Unknown Primary
NCT ID:
NCT07522073
Trial Phases:
Phase III
Protocol IDs:
INCB161734-303 (primary)
NCI-2026-04028
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Incyte Corporation
NCI Full Details:
http://clinicaltrials.gov/show/NCT07522073
Summary
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy
with or without INCB161734 in participants with metastatic pancreatic ductal
adenocarcinoma (PDAC).
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.